GLP1 Analogues.......
These are a few from some of the larger Companies......I'm sure theres other smaller Co.'s with advanced GLP1's that could be licenced out to any Big Pharma if they were looking for a GLP1 that has safety and Tolerability Phasel's done for combo with TT223.
---- Amylin Pharmaceuticals with its already-marketed exenatide formulation Byetta.
----Sanofi-Aventis------ hexalysinated exendin-4 analog AVE0010 (ZP-10)
----Roche------alpha-aminoisobutryic acid-derivatized GLP-1 analog R1583 (BIM 51077)
----GlaxkoSmithKlyne--------- GLP-1-albumin fusion GSK716155
(Albugon).
----Novo-----Liraglutide (don't kid yourself, for the right money and Guaranteed Committment with LARGE Non-Performance Penalties, they could still be a partner if deal was front-end loaded. $50mil upfront say )
----Pfizer-----Acquired BioRexis Feb./07 for GLP1 Transferrin Fusion Technology.
There are other GLP1 Analogues out there that are not as Clinically Developed ....LikeOctoplus' OP-286.....Cellmed's unnamed GLP1.
It's actually the Pfizer technology that stands out for me for the not yet approved category. Pfizer wants into the TYPE2 Diabetes Sector very bad. They found out with Exubera(inhaled Insulin) that Insulin isn't whats needed for most TYPE2 Diabetics. Let alone the terrible side-effects of Snorting Insulin. So they shut down their participation with it late in 2007 and from the looks of things it probably had a lot to do with their acquisition of Biorexis in early 2007. They're now in the GLP1 Development business. Very quiet about it though.
If I were a betting man I'd say Pfizer is one of the 'Interested Parties' watching.
Yup......GPP All